Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +49.56%
#3 DOVU DOVU +49.39%
#4 Velvet Velvet +44.04%
#5 Black Phoenix Black Phoenix +34.54%
#6 τemplar τemplar +23.14%
#7 Cross Cross +18.32%
#8 Ribbita by Virtuals Ribbita by Virtuals +17.09%
#9 Cap Cap +16.96%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.04%
Coin of the day
Glidr Glidr
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Chimeric Therapeutics Limited Chimeric Therapeutics Limited

Chimeric Therapeutics Limited

CHM
Classificação em ações #38385
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical... Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Preço da ação
$0.02468497
Valor de mercado
$1.01M
Variação (1 dia)
-12.50%
Variação (1 ano)
-87.34%
País
AU
Negociar Chimeric Therapeutics Limited (CHM)

Categoria

Healthcare
Lucros da Chimeric Therapeutics Limited (CHM)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Chimeric Therapeutics Limited, os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Chimeric Therapeutics Limited de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE